Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$990.32
▲ $5.63 (+0.6%)
Market data updated: 09/19 01:17 AM
News analyzed: 09/19/2026
Market Cap
$61.28B
Day Range
$989.33 - $1,003.82
52-Week Range
$661.85 - $1,072.75
Beta
—
Next Earnings
22.10.2026
Support
$826.45
Resistance
$1,072.75
ARGX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+36.9% (1Y)
🟢 Strong
Strengths: 4/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Price vs. SMA 50
Price is above the 50-day average
Technical
Biggest negative driver
Death Cross
SMA 50 recently crossed below SMA 200
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Argene (ARGX) demonstrates a robust overall score of 86, driven primarily by strong technical indicators and a near-perfect news sentiment score. The technical category scores an impressive 87, reflecting a clear bullish momentum: the stock price remains above both the 50-day and 200-day moving averages, while the MACD histogram and RSI (62.7) confirm a healthy upward trend. However, the risk category scores only 50, highlighting volatility concerns with an ATR of 2.9% and a Sharpe ratio of 0.73—indicating a 26.2% annualized return but with a 35.8% potential maximum drawdown over three years. The news category’s perfect score of 100 underscores a positive narrative, including bullish analyst upgrades, strategic partnerships (e.g., BenchSci’s AI-driven drug discovery collaboration), and sustained sales growth over 18 consecutive quarters, though some neutral coverage acknowledges valuation debates. The lone concern is declining trading volume despite the price rise, signaling potential weakening institutional interest or liquidity risks.
The stock price is firmly above both the 50-day and 200-day moving averages, with a positive MACD histogram and RSI of 62.7 indicating strong upward momentum. The %K at 57.1 suggests neutral short-term momentum but aligns with broader bullish trends.
This technical strength signals sustained investor confidence and reduces the likelihood of a near-term reversal.
Recent news is overwhelmingly positive, featuring analyst upgrades, strategic partnerships, and consistent sales growth, with only neutral commentary on valuation. The absence of negative headlines further reinforces investor sentiment.
Positive news drives long-term investor interest and can justify premium valuations, especially in biotech where partnerships and clinical progress are critical.
The ATR of 2.9% and a Sharpe ratio of 0.73 reveal moderate volatility, with a 35.8% potential drawdown over three years despite a 26.2% annualized return. This suggests higher risk-adjusted volatility relative to returns.
The risk profile may deter conservative investors or those sensitive to drawdowns, particularly in a sector prone to regulatory or clinical setbacks.
StockIQ conclusion
Argene (ARGX) presents a compelling profile with strong technicals and positive news sentiment, supported by consistent sales growth and strategic partnerships. However, its risk profile—highlighted by volatility and potential drawdowns—remains a notable constraint. The decline in trading volume adds a layer of uncertainty, suggesting that while the fundamentals are favorable, execution and liquidity risks could influence near-term performance. Investors should monitor clinical progress and analyst activity for further clarity.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/08/202660
This Week
86
7D Ago
↓ -26
Weakening
Technical
47
7D Ago: 87
↓ -40
News
98
7D Ago: 100
→ -2
Risk
50
7D Ago: 50
→ 0
Biggest Declines
📊 Score History
60
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
10d ago · $1,033.15
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
10d ago · $1,033.15
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
11d ago · $1,033.15
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
11d ago · $1,033.15
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
12d ago · $1,033.15
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
12d ago · $1,033.15
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
13d ago · $1,033.15
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
13d ago · $1,033.15
Evidence: 9 bullish / 1 bearish technical signals agreeing
What happened after
14d ago · $1,035.24
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
14d ago · $1,035.24
Evidence: 10 bullish / 1 bearish technical signals agreeing
What happened after
15d ago · $1,059.39
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
15d ago · $1,059.39
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
16d ago · $1,047.14
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
16d ago · $1,047.14
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
16d ago · $1,049.95
Evidence: attention score 73/100
What happened after
17d ago · $1,028.51
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
17d ago · $1,028.51
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
17d ago · $1,031.66
Evidence: Euphoria score crossed 55 (now 60)
What happened after
18d ago · $1,031.66
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
18d ago · $1,031.66
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
60 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
83
$1,019.49
Now
60
$990.32
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
47
Risk
50
Sentiment
98
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **argenx SE** highlights its strong financial performance and strategic advancements. The company has maintained **18 consecutive quarters of sales growth**, reinforcing its position as a leader in immunology innovation. Analysts, including Wedbush’s David Nierengarten, have repeatedly rated it **Outperform** with a $1150 price target, praising its long-term potential. Additionally, argenx partnered with **BenchSci** to integrate AI-driven preclinical drug discovery, signaling continued investment in cutting-edge research. Market outperformance over five years (24.86% annualized return) and a $64.63 billion valuation further underscore its growth trajectory.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about argenx SE. News trend score: 98. Reason: 11 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
50
Psychology
32
Fundamentals
—
Technical
47
Valuation
—
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+14%
Market Narrative
60
Fundamental Reality
50
Narrative Gap
+10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ARGX’s psychology is fragmented, with **euphoria** (32) and **herding** (28) dominating despite negative momentum. The 18.2% outperformance above the 200-day average, paired with perfect news sentiment, suggests investors may be anchoring to recent gains while ignoring short-term weakness. Herding behavior—evidenced by underperformance relative to peers—implies passive alignment rather than aggressive conviction. The narrative gap (11) hints at a disconnect between optimistic expectations (61) and neutral technicals (50), raising the question of whether euphoria is sustainable or a speculative bubble waiting for a catalyst. The lack of panic or overconfidence signals keeps the environment cautiously optimistic but vulnerable to external triggers.
Updated: 09/08/2026, 09:45 PM
What could change this?
👥 What the crowd believes
"Argenx Has Delivered 18 Consecutive Quarters of Sales Growth"
"Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target"
"BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery"
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 72/100
🔴 Weakest match
Jack Schwager — 18/100
🗣️ Why do they disagree?
Based on documented principles, the model estimates a sharp divide among historical strategies evaluating ARGX, primarily driven by technical perspectives and fundamental data availability. Samuel Armstrong Nelson's framework finds promise in the stock's cycle position as potentially oversold, whereas technical traders like Jesse Livermore and Jack Schwager penalize the company for its prevailing negative trend and lack of a structured trading setup. Fundamental stalwarts including Benjamin Graham, Philip Fisher, and Peter Lynch end up in neutral territory simply because the model identifies insufficient balance-sheet and growth data to form a conclusive valuation. Concurrently, risk-focused investors like Howard Marks and Morgan Housel urge caution, pointing to late-cycle warning signs and elevated volatility that could unseat patient shareholders.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 72
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 52
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 52
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Morgan Housel
The Psychology of Money (2020)
🟡 49
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 47
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 37
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 37
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 34
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 18
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 5 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 11 positive, 6 neutral, 3 negative out of the last 20 articles.
Yahoo · 17.9.2026
ChartMill · 17.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 8.9.2026
MT Newswires · 8.9.2026
Benzinga · 8.9.2026
SeekingAlpha · 5.9.2026
Benzinga · 4.9.2026
Benzinga · 3.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Yahoo · 2.9.2026
Motley Fool · 2.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
SeekingAlpha · 31.8.2026
Benzinga · 31.8.2026
Yahoo · 28.8.2026
Pharma Voice · 28.8.2026
Yahoo · 28.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for argenx SE (ARGX) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for ARGX specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
ARGX's technical score is 47/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Price is above the 50-day average; Price is above the 200-day average; RSI 54.5 — healthy positive momentum.
Based on the real signals StockIQ computed: SMA 50 recently crossed below SMA 200; MACD histogram is negative — falling momentum; Price is below the SAR point — downtrend.
StockIQ has no recorded dividend payment history for ARGX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,259,349 shares short as of 2026-08-31 · vs. 1,334,571 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
51.2% of trading volume this week was short selling, vs. 56.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology